Antisense psoriasis cream to undergo clincial study
25 July, 2003 by Melissa TrudingerAntisense Therapeutics has announced plans to conduct a pre-Phase I proof-of-concept clinical study to confirm that its antisense psoriasis treatment ATL1101 shows activity.
GM farmer warns no case for canola -- yet
24 July, 2003 by Jeremy TorrNSW farmer Bruce Finney cultivates more than 7000 hectares of GM crops, including soy beans and maize, and fully supports the use of GM cotton. Ask him about GM canola, and he tells a different story.
Gradipore to target chiral market
24 July, 2003 by Jeremy TorrHot on the heels of a new technology-exchange deal with Texas A&M University, Gradipore is to chase the chiral separation market with a product based its membrane purification technology.
GroPep wins patent for infertility drug
22 July, 2003 by Melissa TrudingerGroPep's infertility drug program has received a boost recently with the issue of a patent covering the compound, transforming growth factor beta (TGF-beta).
Ventracor aiming for CE approval by next year
22 July, 2003 by Jeremy TorrVentracor's VentrAssist left ventricular assist device may see market approval as early as next year, according to company CEO, Michael Spooner.
Clone sheep company to cull
22 July, 2003 by Jeremy TorrFollowing Bayer's withdrawal from joint drug developments with Scottish cloning specialists PPL, the company's New Zealand offshoot is to cull its flock of transgenic sheep, and reduce staff numbers.
Eiffel signs asthma drug deal with US company
21 July, 2003 by Jeremy TorrDelivery platform specialist Eiffel Technologies has scored a benchmark deal with US-based asthma drug delivery company, Oriel Therapeutics, to re-engineer asthma drugs optimised for inhaler delivery.
ASX talks up 'Ozdaq' plan
21 July, 2003 by Jeremy TorrThe Australian Stock Exchange is considering an Australian version of the Nasdaq to cater for the special needs of young technology companies -- especially biotechs. And if the regulators agree, the plans could start seeing the light of day in as little as a month or two.
Ambri dumps IP value and reels in $15m
17 July, 2003 by Jeremy TorrSydney bio-nano company Ambri has raised AUD$15.5 million through a placement of ordinary shares to a mix of existing and new institutional investors, and simultaneously announced it will write off $20.7 million worth of IP value from its accounts.
New WEHI facility opens door to drug design
17 July, 2003 by Melissa TrudingerThe head of the structural biology division at Melbourne's Walter and Eliza Hall Institute has tipped "one to two new drugs" will be developed at the facility in the next five years.
ToxiTech investment the latest in Qld biotech funding spree
17 July, 2003 by Pete YoungThe funding floodgates suddenly appear to have swung open for young and not-so-young biotechs -- at least in Queensland.
Leading Australian scientist attacks GM moratoria
17 July, 2003 by Graeme O'NeillWith a nationwide freeze in place on commercial production of genetically modified canola, Australia's leading plant geneticist delivered a warning to GM-shy state governments yesterday: use it, or lose markets.
Agbiotech forum looks back to the future
16 July, 2003 by Jeremy TorrAgricultural scientists and biotech researchers should not concentrate on new biotechnology solutions at the expense of traditional methods -- the latter still have plenty of promise, a recent Sydney forum has been told.
Cardia subsid signs global moth control deal
16 July, 2003 by Melissa TrudingerCardia subsidiary Bioglobal has signed a marketing and distribution agreement with Cotton Growers Services, a joint venture company owned by Bayer CropScience and Syngenta, for a product to control the Heliothis moth.
AGT files more diabetes, obesity patents
16 July, 2003 by Melissa TrudingerAGT Biosciences says it has filed another three patent applications for genes involved in diabetes and obesity.
